Cross-source identity
National Provider Identifier 1356325468 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1356325468 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1356325468 | 79 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1356325468 | 28 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 6b6749bf… | Canonical resolved node · 4 identifier(s) · 2 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $25,910 | 8 |
| Consulting Fee | $15,538 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,870 | 4 |
| Compensation for serving as faculty or as a speaker for a medical education program | $12,155 | 9 |
| Manufacturer | Amount | Records |
|---|---|---|
| Tris Pharma Inc | $699,114 | 17 |
| Supernus Pharmaceuticals, Inc. | $27,548 | 25 |
| Axsome Therapeutics, Inc. | $14,695 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Spravato(Esketamine Hcl) | 103 | $129,584 |
| Auvelity(Dextromethorphan Hbr/Bupropion) | 27 | $40,688 |
| Rexulti(Brexpiprazole) | 11 | $16,278 |
| Vyvanse(Lisdexamfetamine Dimesylate) | 38 | $15,359 |
| Dyanavel Xr(Amphetamine) | 15 | $6,214 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Noven Pharmaceuticals, Inc. (FL) | cms_open_payments |
| ← pays | Corium, Llc (MA) | cms_open_payments |
| $4,459 |
| 25 |
| 15 |
| Noven Pharmaceuticals, Inc. | $12,280 | 10 |
| Corium, Llc | $7,555 | 11 |